Earnings

Cytek Biosciences Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $53.229M Beat $52.800M Estimate

Nov 4, 2026 · 04:27 PM ET· updated 1h ago

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 25 percent decrease over losses of $(0.04) per share from

Why It Matters

Cytek lost less money than expected and sold more stuff than forecast. When a company beats on both counts, it shows things are moving in the right direction.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CTKB5.88

-0.08 (-1.43%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.